173 related articles for article (PubMed ID: 31924259)
1. Occurrence of abscesses during treatment with pazopanib in metastatic renal cancer: a case report.
Puliafito I; Russo A; Sciacca D; Puglisi C; Giuffrida D
J Med Case Rep; 2020 Jan; 14(1):7. PubMed ID: 31924259
[TBL] [Abstract][Full Text] [Related]
2. Pazopanib for the treatment of metastatic renal cell carcinoma.
Pick AM; Nystrom KK
Clin Ther; 2012 Mar; 34(3):511-20. PubMed ID: 22341567
[TBL] [Abstract][Full Text] [Related]
3. Guillain-Barré syndrome in a patient with renal cell carcinoma following the first course of pazopanib therapy.
Koshikawa H; Tsukie T; Kurita A; Fujikura M; Suzuki M; Araki K
J Infect Chemother; 2017 Nov; 23(11):798-799. PubMed ID: 28506529
[TBL] [Abstract][Full Text] [Related]
4. Pazopanib-associated interstitial lung disease in a patient with renal cell carcinoma.
Harada Y; Kakimoto S; Shimizu T
BMJ Case Rep; 2020 Jul; 13(7):. PubMed ID: 32641305
[TBL] [Abstract][Full Text] [Related]
5. Pazopanib-related tumor lysis syndrome in metastatic clear cell renal cell carcinoma: a case report.
van Kalleveen MW; Walraven M; Hendriks MP
Invest New Drugs; 2018 Jun; 36(3):513-516. PubMed ID: 29464464
[TBL] [Abstract][Full Text] [Related]
6. A rare case: Hallucination associated with pazopanib.
Demirci NS; Erdem GU; Dogan M; Ozdemir NY; Zengin N
J Cancer Res Ther; 2015; 11(4):961-2. PubMed ID: 26881556
[TBL] [Abstract][Full Text] [Related]
7. Successful re-administration of Pazopanib in a patient with metastatic renal cell carcinoma and a history of Pazopanib-induced nephrotic syndrome: a case report.
Jeon SY; Lee NR; Yim CY
BMC Nephrol; 2019 Jan; 20(1):1. PubMed ID: 30606155
[TBL] [Abstract][Full Text] [Related]
8. The Role of Pazopanib in Non-Clear Cell Renal Cell Carcinoma: A Systematic Review.
Sneed GT; Lee S; Brown JN; Hammond JM
Clin Genitourin Cancer; 2019 Dec; 17(6):419-424. PubMed ID: 31585694
[TBL] [Abstract][Full Text] [Related]
9. Pazopanib for Non-small Cell Lung Cancer: The First Case Report in Korea.
Jo J; Kim JH; Kim JY; Hyun C; Rhee J; Kwon J; Han S; Kim W
Cancer Res Treat; 2016 Jan; 48(1):393-7. PubMed ID: 25715772
[TBL] [Abstract][Full Text] [Related]
10. The European Medicines Agency review of pazopanib for the treatment of advanced renal cell carcinoma: summary of the scientific assessment of the Committee for Medicinal Products for Human Use.
Nieto M; Borregaard J; Ersbøll J; ten Bosch GJ; van Zwieten-Boot B; Abadie E; Schellens JH; Pignatti F
Clin Cancer Res; 2011 Nov; 17(21):6608-14. PubMed ID: 21976546
[TBL] [Abstract][Full Text] [Related]
11. Pazopanib versus sunitinib for the treatment of metastatic renal cell carcinoma patients with poor-risk features.
Kim JH; Park I; Lee JL
Cancer Chemother Pharmacol; 2016 Aug; 78(2):325-32. PubMed ID: 27324136
[TBL] [Abstract][Full Text] [Related]
12. An indirect comparison of the toxicity of sunitinib and pazopanib in metastatic clear cell renal cancer.
Powles T; Sarwar N; Jones R; Wilson P; Boleti E; Protheroe A; Crabb SJ; Shamash J; Stockdale A; Rashid S; Nathan P; Chowdury S
Eur J Cancer; 2012 Nov; 48(17):3171-6. PubMed ID: 22766517
[TBL] [Abstract][Full Text] [Related]
13. Good tolerability, long-term survival and easy management of side effects in a patient with metastatic renal cell carcinoma treated with pazopanib.
Frascaroli M; Di Cesare P
Tumori; 2014; 100(6):e301-4. PubMed ID: 25688516
[TBL] [Abstract][Full Text] [Related]
14. Severe hyperglycaemia following pazopanib treatment: The role of drug-drug-gene interactions in a patient with metastatic renal cell carcinoma-A case report.
Kuruc Poje D; Božina N; Šimičević L; Žabić I
J Clin Pharm Ther; 2020 Aug; 45(4):628-631. PubMed ID: 32369219
[TBL] [Abstract][Full Text] [Related]
15. [First Hungarian experience with pazopanib therapy for patients with metastatic renal cancer].
Maráz A; Bodrogi I; Csejtei A; Dank M; Géczi L; Küronya Z; Mangel L; Petrányi A; Szûcs M; Bodoky G
Magy Onkol; 2013 Sep; 57(3):173-6. PubMed ID: 24107823
[TBL] [Abstract][Full Text] [Related]
16. Pazopanib-induced severe acute liver injury: A case report.
Choi JW; Yoo JJ; Kim SG; Kim YS; Chin S
Medicine (Baltimore); 2021 Nov; 100(46):e27731. PubMed ID: 34797298
[TBL] [Abstract][Full Text] [Related]
17. Long-term response to pazopanib in an elderly man with mRCC. A case report.
D'Aniello C; Cavaliere C; Pisconti S; Facchini G
Tumori; 2014; 100(6):e305-8. PubMed ID: 25688517
[TBL] [Abstract][Full Text] [Related]
18. [Pazopanib for treatment of renal cell carcinoma and soft tissue sarcomas].
Brotelle T; Bay JO
Bull Cancer; 2014 Jun; 101(6):641-6. PubMed ID: 24977453
[TBL] [Abstract][Full Text] [Related]
19. An open-label extension study to evaluate safety and efficacy of pazopanib in patients with advanced renal cell carcinoma.
Sternberg CN; Davis ID; Deen KC; Sigal E; Hawkins RE
Oncology; 2014; 87(6):342-50. PubMed ID: 25227656
[TBL] [Abstract][Full Text] [Related]
20. Real-World Effectiveness and Tolerability of Pazopanib as First Targeted Therapy in Metastatic Renal Cell Carcinoma: A Retrospective Chart Review in Latin America.
Queiroz Muniz D; Ratto B; Yang H; Zhao J; Jenkins M; Signorovitch J; Dezzani L; Salman P; Lema Medina M; Lopera D; Lerzo G; Del Castillo C; Chacon M; Martin A; Campos-Gomez S
Adv Ther; 2019 Dec; 36(12):3446-3457. PubMed ID: 31630333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
